1

4

1

2

- 5 Catecholaminergic modulation of large-scale network dynamics is tied to the
- 6 reconfiguration of corticostriatal connectivity
- 7 Justine A. Hill¹, Cole Korponay^{2,3}, Betty Jo Salmeron¹, Thomas J. Ross¹, Amy C. Janes¹
- 8 ¹ National Institute on Drug Abuse Intramural Research Program
- 9 Biomedical Research Center 251 Bayview Blvd. 7A Baltimore, MD 21224
- 10 ² McLean Hospital, Belmont, MA
- ³Harvard Medical School, Boston, MA
- 12 **Phone: 667-312-5146**
- 13 Email: Justine.hill@nih.gov
- 14 Running Title: Catecholamine impact on network temporal dynamics

2

15 ABSTRACT

16 Large-scale brain network function is critical for healthy cognition, yet links between such 17 network function, neurochemistry, and smaller-scale neurocircuitry are unclear. Here, we 18 evaluated 59 healthy individuals using resting-state fMRI to determine how network-level temporal dynamics were impacted by two well-characterized pharmacotherapies targeting 19 20 catecholamines: methylphenidate (20mg) and haloperidol (2mg). Network dynamic changes 21 were tested for links with drug-induced alterations in complex corticostriatal connections as this circuit is a primary site of action for both drugs. A randomized, double-blind, placebo-controlled 22 23 design was used. Methylphenidate enhanced time spent in the default mode network (DMN p<0 24 .001) and dorsal attention network (DAN p<0.001) and reduced time in the frontoparietal network (p<0.01). Haloperidol increased time in a sensory motor-DMN state (p<0.01). The 25 26 magnitude of change in network dynamics induced by methylphenidate vs. placebo was correlated with the magnitude of methylphenidate-induced rearrangement of 27 complex corticostriatal connectivity (R=0.32, p=0.014). Haloperidol did not alter 28 29 complex corticostriatal connectivity. Methylphenidate increased time in networks involved in 30 internal (DMN) and external attention (DAN), aligning with methylphenidate's established role 31 in attention. Methylphenidate also significantly changed complex corticostriatal connectivity by altering the relative strength between multiple corticostriatal connections, indicating that 32 methylphenidate may shift which corticostriatal connections are prioritized relative to others. 33 34 Findings further show that these local circuit changes are linked with large scale network 35 function. Collectively, these findings provide a deeper understanding of large-scale network function, set a stage for mechanistic understanding of network engagement, and provide needed 36 37 information to potentially guide medication use based on network-level effects.

3

38 Introduction

Resting-state brain networks have provided critical insight into the macro-scale 39 40 functional organization of the brain, which is implicated in healthy cognition and psychopathology(1-3). A key next step is to understand how the function of these distributed 41 42 brain networks correspond with changes in neurochemistry and more focal functional circuits. While catecholamines, such as dopamine, have been implicated in large-scale network 43 44 function(3-6), more work using emerging methods is needed to gain a deeper understanding of how catecholaminergic agents impact large-scale network function. Collectively, this line of 45 research promises to enhance the field's basic neurobiological understanding of brain network 46 function and will shed light on how well-characterized therapeutics impact the brain on a new 47 48 scale.

49 A novel approach to assess how catecholamines modulate large-scale network function is 50 network temporal dynamics, which is measured using resting-state functional magnetic 51 resonance imaging (fMRI) data. In contrast to static resting state fMRI analyses which calculates 52 the functional connectivity between brain regions across time, thus leading to one value for the 53 entire resting-state scan, temporal dynamics capture how brain network engagement changes 54 across time. The *resting-state* temporal dynamics of large-scale brain networks have been shown 55 to be central to adaptive functioning, as aberrance in resting-state network temporal dynamics is implicated in numerous forms of psychopathology including ADHD(7,8), nicotine 56 57 dependence (9-11), cocaine use disorder (12) and schizophrenia (13,14). Dopaminergic 58 transmission has been directly implicated in one *task-based* analysis of network temporal 59 dynamics, which demonstrated that dopamine modulates the dynamics of brain state transitions relevant to working memory(4). However, the evidence linking catecholaminergic transmission 60

4

61 to resting-state network dynamics is less clear. One study in children with ADHD indicated that 62 the dopamine and norepinephrine agonist methylphenidate normalized disrupted network temporal dynamics at rest(8). The remaining evidence linking catecholamines and resting-state 63 64 network temporal dynamics is indirect but widespread, where aberrant catecholaminergic transmission – particularly dopaminergic transmission – is thought to be a principal disruption in 65 many psychopathologies which reliably exhibit altered network dynamics(7–14). Taken 66 together, the direct influence of catecholaminergic transmission on the intrinsic temporal 67 function of the brain's large-scale networks (e.g., temporal function at rest) remains largely 68 69 unknown, creating a gap in our understanding of how neuromodulators govern this central component of macro-scale brain function. 70 Our previous work in healthy young adults from the Human Connectome Project used 71 72 coactivation pattern analysis (CAP) to define eight transient brain states which include well 73 defined core neurocognitive networks (e.g., the default mode network (DMN), frontoparietal network (FPN), and dorsal attention network (DAN))(15). Here, we apply these state definitions 74 75 to investigate how acute administration of catecholaminergic agents affect the temporal 76 properties of large-scale brain networks during resting-state fMRI scans in healthy adults. 77 Specifically, in one scan condition we administered methylphenidate (MPH), a dopamine and norepinephrine transporter (DAT/NET) reuptake inhibitor which acts globally to increase 78 extracellular dopamine and norepinephrine and has been shown to enhance cognition due to 79 80 MPH's impact on striatal function (16-19). In a second scan condition, we administered

82 In a third scan condition, we administered placebo. These drugs were administered randomly

haloperidol (HAL), a selective antagonist of D2/D3 receptors located primarily in the striatum.

5

across participants and allowed us to probe the impact of catecholaminergic agonism (MPH) and
D2 antagonism (HAL) on temporal dynamics of large-scale brain networks.

85

We then move further to investigate ties between catecholaminergic modulation of 86 macro-scale brain network temporal dynamics and more focal circuitry. On the circuit-level, 87 catecholamines, most notably dopamine, are known to act directly on the striatum and alter 88 89 connectivity between the striatum and the cortex(20). Though most work in fMRI simplifies corticostriatal communication as connectivity between one striatal node and one cortical node, 90 91 corticostriatal circuitry is much more complex. Striatal nodes project to various cortical regions, 92 while in turn, several cortical regions provide collective and summative input onto striatal nodes(21,22). Preclinical data supports the notion that striatal function is shaped by the 93 convergence of multiple cortical inputs rather than input from any one cortical node 94 alone(21,23). Moreover, the role of striatal dopamine (modulated by both MPH and HAL) may 95 be to alter how *multiple inputs* are *integrated* at striatal cells(20). As such, here we conduct 96 97 connectivity profile analysis(24) to characterize how MPH and HAL alter multifaceted corticostriatal configuration profiles. We ultimately aim to determine whether the magnitude of 98 catecholamine-driven change in corticostriatal configuration profiles is tied to the magnitude of 99 100 catecholaminergic modulation of network temporal dynamics. Altogether, our design allows us to establish how dopamine/norepinephrine agonism and D2 antagonism directly impact the 101 102 inherent temporal function of macro-level brain networks and how this is tied to modulation of 103 specific corticostriatal circuitry.

- 104 Methods and Materials
- 105 **Participants**

6

106	Participants included 59 healthy right-handed individuals between the ages 18-55 (Table
107	1). Participants were excluded for contraindications with fMRI scanning. Individuals with mental
108	and physical health diagnoses and/or medications that interfere with the bold signal or alter
109	metabolism of catecholaminergic agents were also excluded (See Supplement for details).
110	Participants were recruited from Baltimore, MD, and surrounding areas. The current study was
111	reviewed and approved by the institutional review board of the National Institutes of Health. All
112	participants provided written informed consent.
113	Study Design
114	All participants underwent resting-state fMRI scanning sessions with 3 drug conditions
115	administered on separate days, in a double-blind placebo-controlled manner: placebo/placebo,
116	HAL/placebo, placebo/MPH. Doses were 2 mg oral HAL and 20 mg oral MPH. Each scanning
117	visit was identical and took place at drug peak: 4-hours post HAL/placebo and 1-hour post
118	MPH/placebo; timed in accordance with absorption rates to ensure high and stable plasma levels
119	of medication during the scan. Prior to any medication administration, participants completed a
120	nursing assessment, and following the scan session, participants met again with nursing staff to
121	assess side effects.

122 Neuroimaging Data

At each scan, data were collected using a Siemens Trio 3T scanner with a 12 channel RF coil. For high-resolution anatomical scan, multi-planar rapidly acquired gradient echo-structural images were obtained with the following parameters (TR=1.9s, TE= 3.51ms, slices=208, matrix=192x256, flip angle 9°, resolution 1.0x1.0x1.0 mm). For the 8-minute resting state scan, gradient-echo, echo planar images were collected using oblique axial scans 30° from AC-PC

7

128	with AP	phase encoding	and the	following	parameters	(TR=2s,	TE=27ms,	flip=78°, vox
		0		0	1	· · · · · ·		1 /

resolution=3.4375x3.4375x4 mm). Total frames were 240 and the first 5 were discarded.

- 130 Images were processed using FMRIB software library (FSL 6.0.0). Images underwent
- brain extraction, registration, spatial smoothing (6mm), high pass temporal filtering (100s), and

132 motion correction via MCFLIRT. Data were further cleaned to reduce motion artifacts using

- 133 Independent Component Analysis via FIX(25,26) through MELODIC. Data were then
- standardized to MNI152 brain image using FLIRT.

135 Pharmacological Impact on Network Temporal Dynamics

136 Previously, Janes et. al(15) performed Co-Activation Pattern Analysis (CAPs) on resting 137 state data from 462 individuals in the Human Connectome Project(27) using 129 ROIs (cortical 138 and striatal ROIs based on functional parcellation(28,29); amygdala ROIs based on anatomical 139 parcellation(30)) and determined eight co-activation patterns (brain states) using k-means 140 clustering. These eight brain states align with previously established resting state networks such 141 as: the DMN, FPN, DAN, SN, and sensorimotor network (SMO) (Supplementary Figure 1). To 142 investigate how these eight brain states behave dynamically at rest under different catecholaminergic drugs, we extracted ROI time courses from the 129 ROIs and conducted 143 144 CAPs using the Capcalc package (https://github.com/bbfrederick/capcalc). The eight states were used to compute state-specific dynamic measures including: 1) total time spent in each state, 2) 145 number of transitions (i.e. entries) into each state, 3) average persistence within the state once a 146 transition into the state had occurred. 147

To determine an effect of drug on temporal dynamics of brain state activity at rest, we ran
a repeated measures ANOVA that tested the drug × brain state interaction on total time.

150	Following a significant drug \times brain state interaction, we ran eight subsequent repeated measures
151	ANOVAs, testing effect of drug on total time in each state. In states where there was a
152	significant drug effect on total time spent in brain state after correcting for multiple comparisons
153	(Bonferroni corrected: .05/8=.00625), two post-hoc paired t-tests compared MPH and HAL to
154	placebo (Bonferroni corrected: .05/2=.025). All ANOVAs and post-hoc t-tests were conducted in
155	R using the following packages: lme4 (1.1-32), lmertest (3.1-3), effectsize (0.8.3), and multcomp
156	(1.4-23). All analyses controlled for age and sex.
157	In brain states which exhibit significant change in total time in state under drug, we
158	investigated whether changes to total time in state were driven by changes in 1) number of
159	transitions to the state or 2) persistence within state. We ran separate post-hoc paired t-tests
160	comparing 1) transitions and 2) persistence between drug of interest to placebo. Post-hoc
161	analyses were Bonferroni corrected to account for all states tested. See supplementary methods
162	for detailed description of transition analysis.
163	Ties between Network Temporal Dynamics and Static Network Function
164	Previous work has theorized that spending more time in the DMN and DAN at opposing
165	times drives enhanced static DMN-DAN anti-correlation(31) – a known marker of healthy
166	cognition(32,33). Separate literature consistently shows that MPH enhances static DMN-DAN
167	anti-correlation(34,35). We aimed to confirm that MPH enhances static DMN-DAN anti-
168	correlation in our sample and tested the conjecture that static DMN-DAN anti-correlation is
169	driven by DMN and DAN temporal dynamics. To do so, we obtained DMN-DAN anti-
170	correlation values by regressing the whole brain 4D data on the spatial patterns of DAN and
171	DMN states using MATLAB 2022b. Correlation values between each network's time course
172	were computed and Z-transformed using Fisher's R-to-Z. We then tested effect of drug on

9

173	DMN-DAN anti-correlation with a repeated measures ANOVA and post-hoc t-tests (Bonferroni
174	corrected). Next, we tested the relationship between static DMN-DAN anti-correlation and
175	combined time spent in DMN and DAN, hypothesizing that increased time in DMN and DAN
176	would be associated with greater magnitude of DMN-DAN anti-correlation (based on previous
177	proposal(31)). We fit a linear mixed model in R to estimate DMN-DAN anti-correlation score
178	from time in DMN and DAN state combined (summed), when controlling for age, sex, drug, and
179	drug \times time in state interaction.
180	Pharmacological Impact on Corticostriatal Configuration
181	To detect complex changes in corticostriatal connectivity, we conducted connectivity
182	profile analysis(24). Striatal function is shaped by the convergence of multiple cortical inputs

more so than by any one cortical node alone(21,23). Here, connectivity profile analysis allowed
us to model the multifaceted input received by striatal nodes from diverse areas of cortex, and
study drug-related changes in the properties of these "corticostriatal configuration profiles"
(CSCPs)(24).

187 To derive CSCPs, time courses were first extracted from each voxel of a striatal mask(24) and from 53 cortical ROIs (used in CAPs states(15)). Correlation values between time 188 189 courses at each striatal voxel and each cortical ROI were calculated, then r values were Ztransformed using Fisher's R-to-Z. Next, CSCP metrics were calculated in MATLAB (2022b) 190 (For details, see Korponay et al (2022), and Supplement). Briefly, CSCP metrics include 1) 191 192 aggregate divergence (AD): absolute sum of the change in connectivity for each ROI at each striatal voxel (drug – placebo), acting as a measure of absolute change in magnitude of 193 194 connectivity under drug; 2) rank order rearrangement (ROR): the absolute sum of change in 195 order of strength of connectivity for each ROI at each striatal voxel (drug – placebo), acting as a

10

196	measure of absolute change in relative connectivity under drug; 3) entropy shift (ES): change in
197	distribution of the strength of corticostriatal connectivity values under drug compared to placebo.
198	Here, CSCPs were conducted entirely within-subject. Because CSCP metrics inherently compare
199	drug to placebo, we also conducted within-session placebo CSCP metrics for statistical analysis
200	(PBO _{firsthalf} -PBO _{secondhalf}). This score compared the first and second half of placebo data. In total,
201	scores were derived across three conditions: MPH-PBO, HAL-PBO, PBO _{firsthalf} -PBO _{secondhalf} .
202	To determine statistical significance, we calculated subject-wise average scores of each
203	CSCP metric for each condition. We then ran three repeated measures ANOVAs – one for each
204	metric (AD, ROR, ES) – comparing the drug conditions (Bonferroni corrected). If significant,
205	post-hoc t-tests compared MPH-PBO, HAL-PBO and PBO _{firsthalf} -PBO _{secondhalf} (Bonferroni
206	corrected). Where post-hoc t-test revealed a significant drug effect, we then aimed to identify
207	specific areas of the striatum which were significantly altered by drug. We computed subject-
208	level striatal maps of significant CSCP metrics. We then performed a voxel-wise paired t-test
209	between significant drug-placebo and within-session placebo condition using SPM12.
210	Ties between Modulation of Network Temporal Dynamics and Corticostriatal
211	Reconfiguration
212	We tested whether, under the same drug, significant change in network temporal
213	dynamics was related to significant alterations in CSCP metrics. To do so, first we calculated one

subject-wise score of absolute change in time spent in states under drug. Absolute change in time

states (time_{stateN} under drug – time_{stateN} under placebo). We then tested the relationship between

spent in states was derived by summing the absolute value of change in time in each of the eight

215

subject-wise score of significant CSCP metric and absolute change in time spent in states. Where

J C I

there was a significant relationship, we aimed to confirm that this relationship, involving change

219	in time spent in all states, was specifically driven by change in time spent in states whose
220	temporal dynamics were determined to be significantly modulated by drug. The goal of this
221	confirmation was to parse out which networks are involved in the relationship between temporal
222	dynamic network properties and functional corticostriatal circuitry. This was assessed by
223	comparing correlations(36) where x remained CSCP score while y varied as absolute change in:
224	total time spent in all eight states, total time spent in states significantly altered by drug, and total
225	time spent in states not significantly altered by drug. See exact equations in supplementary
226	methods.
227	We conducted further exploratory post-hoc analysis to localize which striatal nodes and
228	individual networks are involved in significant relationships. In contrast to a CSCP score defined
229	as the mean CSCP score at all striatal voxels per subject, node-specific CSCP scores were
230	derived from the mean of voxels in each significant striatal node identified in the voxel-wise t-
231	test. Correlations were calculated between node-specific CSCP scores and change in time spent
232	in each state significantly modulated by drug.
233	
234	Results
235	Network Temporal Dynamics
236	We first tested for effect of drug on total time spent in brain states. There was a
237	significant effect of brain state (F(16,928)=19.53, p<0.001) and a drug \times brain state interaction
238	(F(16,928)=5.78, p<0.001) on total time spent in brain states. A significant effect of drug was
239	noted for the DMN (F(2,116)=15.29, $p_{corr} < 0.001$, $\eta^2 = 0.21$), DAN (F(2,116)=12.42, $p_{corr} < 0.001$,

12

240
$$\eta^2$$
=0.18), FPN (F(2,116)=5.95, p_{corr}<0.05, η^2 =0.09) and sensorimotor-occipital DMN (SM-

241 DMN) state (F(2,116)=9.97,
$$p_{corr} < 0.001$$
, $\eta^2 = 0.15$).

Post-hoc analysis revealed that relative to placebo, MPH increased time spent in the 242 243 DMN (p_{corr}<0.001, d=0.74) and DAN states (p_{corr}<0.001, d=0.665). Increased time was explained by MPH increasing the number of transitions into the DMN (p_{corr}<0.001, d=0.72) and DAN 244 245 states (p_{corr}<0.001, d=0.78). In contrast, MPH had no impact on persistence in either state 246 (p_{corr}>0.05). Given that the DMN and DAN play substantial roles in internal(37–40) and external attention(37,41), respectively, this finding builds on previous literature of MPH's known role in 247 248 attentional enhancement and provides novel insight whereby MPH inherently increases 249 transitions into attention-related networks. MPH also reduced the time spent in the FPN state relative to placebo (p_{corr}<0.01, d=-0.445) and reduced transitions into this state at a significance 250 251 level that did not withstand Bonferroni correction (p_{corr}=0.17) without influencing persistence $(p_{corr} > 0.05)$ (Figure 1A-C). 252 253 Relative to placebo, HAL increased the time spent in the SM-DMN, which represents the 254 co-activation of sensory motor regions and the DMN (p_{corr}<0.01, d=0.49). HAL increased the 255 number of transitions into this state ($p_{corr}=0.013$, d=0.48) and increased the persistence within the 256 SM-DMN at a level that did not withstand Bonferroni correction (p_{corr}=0.054) (Figure 1A-C). 257 The effect of HAL on sensory motor-related state dynamics fits with previous findings demonstrating that HAL impacts sensory motor systems(42) and demonstrates that MPH and 258 259 HAL impact the inherent temporal function of different large-scale networks.

260 DAN / DMN Anti-correlation

261	There was a significant effect of drug on the DMN-DAN anti-correlation ($F(2,116)=11.6$,
262	p<0.001, η^2 =0.17). Post-hoc comparisons confirmed that MPH had a significantly greater
263	magnitude of static DMN-DAN anti-correlation versus placebo (Figure 2A, p _{corr} =0.0014,
264	d=0.57) which aligns with previous literature(34,35), whereas HAL did not significantly differ
265	from placebo (p_{corr} >0.05). We then tested the hypothesis that greater magnitude of static DMN-
266	DAN anti-correlation could be driven by increased time spent in both the DMN and DAN. Time
267	in DMN and DAN combined negatively estimated DMN-DAN correlation independently of drug
268	conditions (Figure 2B, p<0.001, conditional R^2 =0.72, marginal R^2 =0.59). This lends significant
269	evidence towards the conjecture(31) that enhanced anti-correlation of the DMN and DAN is
270	driven by spending more time both states, at opposing times.
271	Corticostriatal Configurations
272	We measured catecholaminergic manipulation of corticostriatal circuitry by measuring
273	effect of drug on CSCP metrics: AD, ROR, and ES. There was a significant effect of drug on
274	ROR, the measure of absolute change in <i>relative</i> corticostriatal connectivity, following repeated
275	measures ANOVA (F(2,116)=15.36, $p_{corr} < 0.001$, $\eta^2 = 0.21$). There was no effect of drug on AD or
276	ES (p_{corr} >0.05), which measure the absolute magnitude of change in corticostriatal connectivity
277	values and change in distribution of the strength of corticostriatal connectivity values,
278	respectively. Post-hoc comparisons revealed that the MPH-PBO condition exhibited significantly
279	higher ROR compared to within-session placebo (p _{corr} <0.001, d=0.86) and HAL-PBO
280	(p _{corr} <0.001, d=0.73; Figure 3A). There was no difference between HAL-PBO and within-
281	session placebo (p_{corr} >0.05). This result shows that corticostriatal connectivities which were
282	relatively weaker under placebo became relatively stronger under methylphenidate and vice
283	versa, at a statistically significant level when measuring total amount of change in relative

14

strength. Thus, we provide evidence that elevated extracellular dopamine and norepinephrine
alter which specific corticostriatal connections are the strongest or weakest, where this
"*reshuffling*" of the relative connectivity strength of cortical regions with the striatum potentially
reflects a shift in the priority of corticostriatal communications.

To localize striatal nodes where MPH significantly induced higher magnitude of ROR compared to placebo, we conducted a voxel-wise paired t-test of striatal ROR value maps comparing MPH-PBO to within-session placebo. This revealed five clusters where MPH significantly induced higher magnitude of ROR compared to placebo: right dorsal caudate; left dorsal caudate; right nucleus accumbens and ventral caudate; left nucleus accumbens; left ventral caudate (Supplementary Table 1). See supplementary results for details on how cortical regions changed in rank order at significant striatal clusters.

295 Network Temporal Dynamics × Corticostriatal Configurations

296 To determine links between smaller-scale circuitry and the time-varying engagement of 297 large-scale networks, we tested associations between significant corticostriatal reconfiguration 298 and change in network temporal dynamics under the same drug. MPH both significantly increased the absolute change in relative corticostriatal connectivity (ROR) and altered network 299 300 temporal dynamics (Figure 1 and 3). We thus tested the association between magnitude of ROR 301 and change in time spent in network-aligned brain states under MPH. There was a significant 302 positive relationship between magnitude of ROR (averaged across the entire striatum) and absolute change in time spent in all brain states under MPH (R=0.29, p=0.025). 303

We examined whether this relationship was driven by change in time spent in the FPN, DMN and DAN states, as we determined that MPH significantly altered the time spent in these

306	three states (Figure 1A). There was a significant relationship between magnitude of ROR and
307	absolute change in time spent in FPN, DMN and DAN states under MPH (R=0.32, p=0.014)
308	while there was no significant relationship between magnitude of ROR and absolute change in
309	time spent in all states excluding FPN, DMN and DAN (R=0.12, p>.05) (Figure 4). The
310	relationship between magnitude of ROR and absolute change in time spent in all states was
311	significantly stronger than the relationship involving change in time spent in states excluding
312	FPN, DMN, DAN states (z=1.87, p=0.031) and not significantly different from the relationship
313	involving only absolute change in time spent in FPN, DMN and DAN states (z=0.37, p>0.05)
314	(Figure 4). We thus concluded that MPH-induced change in time spent in FPN, DMN and DAN
315	combined is principally responsible for the association between MPH-induced change in time
316	spent in all states and magnitude of corticostriatal ROR.
317	In an exploratory analysis, we aimed to localize specific striatal nodes where magnitude
318	of ROR may be associated with change in time spent in the FPN, DMN or DAN. We averaged
319	ROR values for each subject at each of the five striatal nodes previously identified
320	(Supplementary Table 1). We then tested associations between node-wise ROR and change in
321	time spent in FPN, DMN and DAN independently – ultimately yielding 15 correlation tests (5
322	nodes \times 3 brain states). Change in time spent in the DMN alone was significantly positively
323	related to ROR at the left dorsal striatum (Figure 5B, R=0.4, p_{uncorr} =0.0015; p_{corr} =0.0225). The
324	positive relationship with the right dorsal striatum (Figure 5D, R=0.35, p_{uncorr} =0.006, p_{corr} >0.05)
325	did not survive multiple comparisons correction. However, these relationships did not
326	significantly differ from each other ($z=-0.87$, $p>0.05$). No other relationships were significant
327	following multiple comparisons correction. These exploratory findings demonstrate that the
328	magnitude at which MPH reshuffles the relative connectivity strength between different cortical

16

regions and the dorsal caudate is associated with the amount that MPH enhances time spent in the DMN at rest.

331

332 Discussion

Methylphenidate increased the amount of time spent in the DMN and DAN states by 333 334 increasing the frequency of transitions into both states. This finding is compelling given MPH's known role in attention and the fact that both states play a role in different types of attention. 335 336 While the DMN plays a critical role in processes requiring internally focused attention such as 337 episodic memory(37–40), the DAN is involved in the regulation of external attention, which is 338 required to meet external task demands(37,41). Thus, even at rest, MPH facilitates dynamic 339 transitions into attentional states, suggesting that MPH primes the brain to engage in both 340 internal and external attentional demands. MPH also suppressed the amount of time spent in the 341 FPN. Previous work has shown that the FPN facilitates goal-directed behavior via flexible switching between the DMN and the DAN to accomplish an internally or externally oriented 342 343 task, respectively(37). Consistent with theories which posit MPH enhances cognitive efficiency(43), the suppression of time spent in the FPN coupled with enhanced entries into 344 345 DMN and DAN may indicate that under MPH, less FPN-related effort is needed to facilitate goal-directed attention. 346

In a follow-up analysis, we confirmed that in addition to enhancing time spent in DMN and DAN, MPH strengthens static DMN-DAN anti-correlation. Stronger anti-correlation between the DMN and the DAN at rest is a known marker of healthy cognition(44), and it has been hypothesized that increased anti-correlation of these networks is driven by increased time

17

351	spent in both brain networks, at opposing times(31). Here, we prove this conjecture that a
352	stronger DMN-DAN anti-correlation is related to increased time in both DMN and DAN states.
353	Our findings thus show that MPH drives changes in network temporal dynamics which explain
354	known markers of cognitive enhancement identified by static functional connectivity measures.
355	Pharmacological challenge by HAL, in contrast, increased the amount of time in the SM-
356	DMN brain state. Though it may appear counterintuitive that both MPH and HAL enhanced time
357	in DMN-related states, the DMN and SM-DMN states are neurobiologically distinct
358	representations of co-activated patterns(15). The enhancement of a SM-related network fits with
359	known effects of antipsychotics on sensorimotor systems(42). Moreover, HAL is used as a first-
360	line medication to treat schizophrenia, a disorder which exhibits altered temporal function of SM
361	and DMN(14,45). The current finding in healthy controls that acute HAL enhances temporal
362	function of two networks temporally disrupted in those with schizophrenia underscores the
363	necessity of considering pharmacological impact of medication when analyzing temporal
364	network function in clinical populations. This consideration may clarify mixed findings in the
365	field(45).
366	Given that MPH and HAL have heightened locus of action at the striatum and act to
367	modulate large-scale brain networks, we assessed how MPH and HAL impact corticostriatal
368	function and whether this relates to drug-induced changes in network temporal dynamics. We
369	obtained CSCPs, which aim to capture complex functional corticostriatal interactions by
370	quantifying collective and relative connectivity between multiple cortical regions and striatal

nodes, as AD, ROR, and ES. Challenge by HAL had no effect on CSCP measures. Challenge by

372 MPH, in contrast, altered ROR but did not alter AD or ES. Previous work also has shown that

each configuration property (AD, ROR, ES) is modulated independently and likely represents

18

distinct neurobiological properties which may differentially shape striatal node function(24). We
build on this to show that different pharmacological agents have distinct action on configuration
profiles.

377 In altering ROR alone, MPH specifically acts to *reshuffle* the order of which corticostriatal connections are relatively greater or weaker at distinct striatal nodes. In doing so, 378 379 MPH appears to rearrange the influence that different corticostriatal communications have(46) to 380 ultimately contribute to altered brain function. It may be, at least in part, that MPH acting at the 381 striatum significantly alters how cortical input is integrated in striatal cells(20) - though given 382 MPH's global action and effects on catecholamines broadly, future work is needed to disentangle 383 this assertion. MPH-induced ROR occurs significantly at bilateral counterparts in the dorsal caudate and at the right and left nucleus accumbens and ventral caudate. Anatomically, these 384 385 striatal nodes are engaged in bi-directional corticostriatal loops(47), and functionally, the dorsal caudate is tied to FPN while the ventral nodes identified here are linked to the DMN and limbic 386 network(28). 387

Importantly, we provide novel evidence that MPH-induced corticostriatal ROR is tied to 388 MPH-induced change in network temporal dynamics. The magnitude of ROR at the left and right 389 390 dorsal caudate nodes are independently positively associated with network dynamic change; 391 particularly related to enhancement of time spent in the DMN state. Translational research has established that the dopamine system and corticostriatal circuits, involving the dorsal caudate 392 393 specifically, are implicated in addiction, ADHD, and the pharmacological action of MPH in the 394 treatment of ADHD(48–51). More recent evidence has built on this historical understanding to illustrate that activity of neurocognitive networks, particularly DMN, is aberrant in these 395 disorders(3,7,9,52,53). However, a gap remains in linking the often more pre-clinical body of 396

19

397	circuit-based evidence to large-scale brain network function. Our findings reveal a link between
398	MPH-induced changes in functional corticostriatal circuitry and temporal dynamic function of
399	the DMN. These results may suggest that dopaminergic agonism alters how cortical connections
400	with the dorsal caudate are prioritized, leading to changes in temporal dynamic function of brain
401	networks, particularly the DMN. If this is true, it would expand on theory that static DMN
402	functional connectivity is modulated by D2/D3 receptors(3) and suggest a specific locus and
403	mechanism of regulation at the dorsal caudate, a striatal region functionally defined by its role in
404	cognitive control(28,54).
405	Limitations
406	A limitation of this present work is that baseline dopaminergic function was not assessed
407	using PET. This may be relevant as others have shown that individual variance in dopaminergic

409 with no clinical appearance of dopaminergic disruptions. We also used a within-subjects design,

function may impact the action of MPH(55,56). However, the current participants were healthy

410 which reduces the impact of individual variance. While we defined a relationship between

411 temporal dynamics and corticostriatal configuration, we relied on correlational analyses and are

412 unable to determine a causal relationship between these changes. As articulated in the discussion,

413 we speculated that changes in corticostriatal interactions may drive the influence of MPH on

414 temporal dynamic function; this hypothesis needs to be confirmed in future work. However, even

in the absence of a causal link, we provide comprehensive evidence of MPH's impact on

temporal dynamics and related static resting state features that differ significantly from HAL.

417 Conclusion

418	We find that pharmacological agents – MPH and HAL – have distinct impacts on
419	network temporal dynamics and on corticostriatal configuration. Temporal dynamic findings
420	suggest that MPH may prime the brain to engage in external or internal oriented attention,
421	revealing a novel understanding of MPH action in alignment with the known impact of MPH on
422	attention. Further, we show that while HAL does not alter corticostriatal configurations, MPH
423	specifically alters ROR, acting to reshuffle the relative connectivity strength of multiple cortical
424	regions with the striatum. The magnitude of this 'reshuffling', across the striatum and
425	specifically at dorsal caudate is tied to MPH-induced change in brain network temporal
426	dynamics, particularly the DMN. Thus, this work suggests that MPH-induced changes in dorsal
427	caudate communication with the cortex may play a role in driving the time-varying engagement
428	of the DMN and other large-scale brain networks, though future work is required to determine
429	the causality of this association. Our findings ultimately uncover catecholamine-driven links
430	between nuanced corticostriatal circuitry and large-scale brain network temporal dynamics,
431	paving the way for a mechanistic understanding of the neurochemistry and neurocircuitry
432	governing macro-scale brain network engagement.

21

434 Acknowledgments

- 435 This work was supported by the National Institute on Drug Abuse Intramural Research Program
- 436 We thank Dr. Blaise Frederick for his assistance in applying co-activation pattern analysis to this
- 437 data.

22

438 **Conflict of Interest**

439 The authors declare no conflict of interest.

23

440 **References**

- Menon V, D'Esposito M. The role of PFC networks in cognitive control and executive function. Neuropsychopharmacol. 2022 Jan;47(1):90–103.
- 443 2. Menon V. Large-scale brain networks and psychopathology: a unifying triple network
 444 model. Trends in Cognitive Sciences. 2011 Oct 1;15(10):483–506.
- 3. Zhang R, Volkow ND. Brain default-mode network dysfunction in addiction. NeuroImage.
 2019 Oct 15;200:313–31.
- 4. Braun U, Harneit A, Pergola G, Menara T, Schäfer A, Betzel RF, et al. Brain network
 dynamics during working memory are modulated by dopamine and diminished in
 schizophrenia. Nat Commun. 2021 Jun 9;12(1):3478.
- de la Cruz F, Wagner G, Schumann A, Suttkus S, Güllmar D, Reichenbach JR, et al.
 Interrelations between dopamine and serotonin producing sites and regions of the default mode network. Hum Brain Mapp. 2020 Oct 31;42(3):811–23.
- 6. Shafiei G, Zeighami Y, Clark CA, Coull JT, Nagano-Saito A, Leyton M, et al. Dopamine
 Signaling Modulates the Stability and Integration of Intrinsic Brain Networks. Cerebral
 Cortex (New York, NY). 2019 Jan;29(1):397.
- Cai W, Chen T, Szegletes L, Supekar K, Menon V. Aberrant Time-Varying Cross-Network
 Interactions in Children With Attention-Deficit/Hyperactivity Disorder and the Relation to
 Attention Deficits. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging. 2018
 Mar 1;3(3):263–73.
- 460 8. Mizuno Y, Cai W, Supekar K, Makita K, Takiguchi S, Tomoda A, et al. Methylphenidate
 461 remediates aberrant brain network dynamics in children with attention-deficit/hyperactivity
 462 disorder: A randomized controlled trial. Neuroimage. 2022 Aug 15;257:119332.
- 9. Quam A, Biernacki K, Ross TJ, Salmeron BJ, Janes AC. Childhood Trauma, Emotional
 Awareness, and Neural Correlates of Long-Term Nicotine Smoking. JAMA Netw Open.
 2024 Jan 11;7(1):e2351132.
- 466 10. Wang KS, Kaiser RH, Peechatka AL, Frederick BB, Janes AC. Temporal Dynamics of
 467 Large-Scale Networks Predict Neural Cue Reactivity and Cue-Induced Craving. BPS: CNNI.
 468 2020 Nov 1;5(11):1011–8.
- 469 11. Wang KS, Brown K, Frederick BB, Moran LV, Olson D, Pizzagalli DA, et al. Nicotine
 470 acutely alters temporal properties of resting brain states. Drug Alcohol Depend. 2021 Sep
 471 1;226:108846.
- I2. Zhai T, Gu H, Salmeron BJ, Stein EA, Yang Y. Disrupted Dynamic Interactions Between
 Large-Scale Brain Networks in Cocaine Users Are Associated With Dependence Severity.
 Biological Psychiatry: Cognitive Neuroscience and Neuroimaging. 2023 Jun 1;8(6):672–9.

 Kottaram A, Johnston L, Ganella E, Pantelis C, Kotagiri R, Zalesky A. Spatio-temporal dynamics of resting-state brain networks improve single-subject prediction of schizophrenia diagnosis. Hum Brain Mapp. 2018 Sep;39(9):3663–81. Kottaram A, Johnston LA, Cocchi L, Ganella EP, Everall I, Pantelis C, et al. Brain network dynamics in schizophrenia: Reduced dynamism of the default mode network. Hum Brain Mapp. 2019 Jan 21;40(7):2212–28. Janes AC, Peechatka AL, Frederick BB, Kaiser RH. Dynamic functioning of transient resting-state coactivation networks in the Human Connectome Project. Human Brain Mapping. 2020;41(2):373–87. Kodama T, Kojima T, Honda Y, Hosokawa T, Tsutsui K ichiro, Watanabe M. Oral Administration of Methylphenidate (Ritalin) Affects Dopamine Release Differentially Between the Prefrontal Cortex and Striatum: A Microdialysis Study in the Monkey. J Neurosci. 2017 Mar 1;37(9):2387–94. Yan den Bosch R, Lambregts B, Määttä J, Hofmans L, Papadopetraki D, Westbrook A, et al Striatal dopamine dissociates methylphenidate effects on value-based versus surprise-based reversal learning. Nat Commun. 2022 Aug 24;13:4962. Westbrook A, van den Bosch R, Määttä J, Hofmans L, Papadopetraki D, Cools R, et al. Dopamine promotes cognitive effort by biasing the benefits versus costs of cognitive work. Science. 2020 Mar 20;367(6484):1362–6. Wilens TE. Effects of Methylphenidate on the Catecholaminergic System in Attention- Deficit/Hyperactivity Disorder. Journal of Clinical Psychopharmacology. 2008 Jun;28(3):S46. Moyer JT, Wolf JA, Finkel LH. Effects of Dopaminergic Modulation on the Integrative Properties of the Ventral Striatal Medium Spiny Neuron. Journal of Neurophysiology. 2007 Dec;98(6):3731–48. Chret AG, Soler-Llavina GJ, Sabatini BL. Timing and location of synaptic inputs determin modes of subtreshold integration in striatal medium spiny neurons. J Neurosci. 2007 Aug 15;27(33):8967–77. Ch			
 Kottaram A, Johnston LA, Cocchi L, Ganella EP, Everall I, Pantelis C, et al. Brain network dynamics in schizophrenia: Reduced dynamism of the default mode network. Hum Brain Mapp. 2019 Jan 21;40(7):2212–28. Janes AC, Peechatka AL, Frederick BB, Kaiser RH. Dynamic functioning of transient resting-state coactivation networks in the Human Connectome Project. Human Brain Mapping. 2020;41(2):373–87. Kodama T, Kojima T, Honda Y, Hosokawa T, Tsutsui K ichiro, Watanabe M. Oral Administration of Methylphenidate (Ritalin) Affects Dopamine Release Differentially Between the Prefrontal Cortex and Striatum: A Microdialysis Study in the Monkey. J Neurosci. 2017 Mar 1;37(9):2387–94. van den Bosch R, Lambregts B, Määttä J, Hofmans L, Papadopetraki D, Westbrook A, et al Striatal dopamine dissociates methylphenidate effects on value-based versus surprise-based reversal learning. Nat Commun. 2022 Aug 24;13:4962. Westbrook A, van den Bosch R, Määttä J, Hofmans L, Papadopetraki D, Cools R, et al. Dopamine promotes cognitive effort by biasing the benefits versus costs of cognitive work. Science. 2020 Mar 20;367(6484):1362–6. Wilens TE, Effects of Methylphenidate on the Catecholaminergic System in Attention- Deficit/Hyperactivity Disorder. Journal of Clinical Psychopharmacology. 2008 Jun;28(3):S46. Moyer JT, Wolf JA, Finkel LH, Effects of Dopaminergic Modulation on the Integrative Properties of the Ventral Striatal Medium Spiny Neuron. Journal of Neurophysiology. 2007 Dec;98(6):3731–48. Carter AG, Soler-Llavina GJ, Sabatini BL. Timing and location of synaptic inputs determin modes of subthreshold integration in striatal medium spiny neurons. J Neurosci. 2007 Aug 15;27(33):8967–77. Choi EY, Ding SL, Haber SN. Combinatorial Inputs to the Ventral Striatum from the Temporal Cortex, Frontal Cortex, and Amygdala: Implications for Segmenting the Striatum eNeuro. 2017;4(6):ENEURO.0392-17.2017. Korponay C, Stein EA	475 476 477	13.	Kottaram A, Johnston L, Ganella E, Pantelis C, Kotagiri R, Zalesky A. Spatio-temporal dynamics of resting-state brain networks improve single-subject prediction of schizophrenia diagnosis. Hum Brain Mapp. 2018 Sep;39(9):3663–81.
 Janes AC, Peechatka AL, Frederick BB, Kaiser RH. Dynamic functioning of transient resting-state coactivation networks in the Human Connectome Project. Human Brain Mapping. 2020;41(2):373–87. Kodama T, Kojima T, Honda Y, Hosokawa T, Tsutsui K ichiro, Watanabe M. Oral Administration of Methylphenidate (Ritalin) Affects Dopamine Release Differentially Between the Prefrontal Cortex and Striatum: A Microdialysis Study in the Monkey. J Neurosci. 2017 Mar 1;37(9):2387–94. Yan den Bosch R, Lambregts B, Määttä J, Hofmans L, Papadopetraki D, Westbrook A, et al Striatal dopamine dissociates methylphenidate effects on value-based versus surprise-based reversal learning. Nat Commun. 2022 Aug 24;13:4962. Westbrook A, van den Bosch R, Määttä JI, Hofmans L, Papadopetraki D, Cools R, et al. Dopamine promotes cognitive effort by biasing the benefits versus costs of cognitive work. Science. 2020 Mar 20;367(6484):1362–6. Wilens TE. Effects of Methylphenidate on the Catecholaminergic System in Attention- Deficit/Hyperactivity Disorder. Journal of Clinical Psychopharmacology. 2008 Jun;28(3):S46. Moyer JT, Wolf JA, Finkel LH. Effects of Dopaminergic Modulation on the Integrative Properties of the Ventral Striatal Medium Spiny Neuron. Journal of Neurophysiology. 2007 Dec;98(6):3731–48. Carter AG, Soler-Llavina GJ, Sabatini BL. Timing and location of synaptic inputs determinm modes of subthreshold integration in striatal medium spiny neurons. J Neurosci. 2007 Aug 15;27(33):8967–77. Choi EY, Ding SL, Haber SN. Combinatorial Inputs to the Ventral Striatum from the Temporal Cortex, Frontal Cortex, and Amygdala: Implications for Segmenting the Striatum 6Nurosci. 2017;4(6):ENEURO.0392-17.2017. Korponay C, Choi EY, Haber SN. Corticostriatal Projections of Macaque Area 44. Cereb Cortex Commun. 2020 Nov 5;1(1):tgaa079. Korponay C, Stein EA, Ross TJ. Misconfigured striatal connectivity profiles in smokers. Neuropsych	478 479 480	14.	Kottaram A, Johnston LA, Cocchi L, Ganella EP, Everall I, Pantelis C, et al. Brain network dynamics in schizophrenia: Reduced dynamism of the default mode network. Hum Brain Mapp. 2019 Jan 21;40(7):2212–28.
 Kodama T, Kojima T, Honda Y, Hosokawa T, Tsutsui K ichiro, Watanabe M. Oral Administration of Methylphenidate (Ritalin) Affects Dopamine Release Differentially Between the Prefrontal Cortex and Striatum: A Microdialysis Study in the Monkey. J Neurosci. 2017 Mar 1;37(9):2387–94. van den Bosch R, Lambregts B, Määttä J, Hofmans L, Papadopetraki D, Westbrook A, et al Striatal dopamine dissociates methylphenidate effects on value-based versus surprise-based reversal learning. Nat Commun. 2022 Aug 24;13:4962. Westbrook A, van den Bosch R, Määttä JI, Hofmans L, Papadopetraki D, Cools R, et al. Dopamine promotes cognitive effort by biasing the benefits versus costs of cognitive work. Science. 2020 Mar 20;367(6484):1362–6. Wilens TE. Effects of Methylphenidate on the Catecholaminergic System in Attention- Deficit/Hyperactivity Disorder. Journal of Clinical Psychopharmacology. 2008 Jun;28(3):S46. Moyer JT, Wolf JA, Finkel LH. Effects of Dopaminergic Modulation on the Integrative Properties of the Ventral Striatal Medium Spiny Neuron. Journal of Neurophysiology. 2007 Dec;98(6):3731–48. Carter AG, Soler-Llavina GJ, Sabatini BL. Timing and location of synaptic inputs determin modes of subthreshold integration in striatal medium spiny neurons. J Neurosci. 2007 Aug 15;27(33):8967–77. Choi EY, Ding SL, Haber SN. Combinatorial Inputs to the Ventral Striatum from the Temporal Cortex, Frontal Cortex, and Amygdala: Implications for Segmenting the Striatum eNeuro. 2017;4(6):ENEURO.0392-17.2017. Korponay C, Choi EY, Haber SN. Corticostriatal Projections of Macaque Area 44. Cereb Cortex Commun. 2020 Nov 5;1(1):tgaa079. Korponay C, Stein EA, Ross TJ. Misconfigured striatal connectivity profiles in smokers. Neuropsychopharmacol. 2022 Nov;47(12):2081–9. 	481 482 483	15.	Janes AC, Peechatka AL, Frederick BB, Kaiser RH. Dynamic functioning of transient resting-state coactivation networks in the Human Connectome Project. Human Brain Mapping. 2020;41(2):373–87.
 17. van den Bosch R, Lambregts B, Määttä J, Hofmans L, Papadopetraki D, Westbrook A, et al Striatal dopamine dissociates methylphenidate effects on value-based versus surprise-based reversal learning. Nat Commun. 2022 Aug 24;13:4962. 18. Westbrook A, van den Bosch R, Määttä JI, Hofmans L, Papadopetraki D, Cools R, et al. Dopamine promotes cognitive effort by biasing the benefits versus costs of cognitive work. Science. 2020 Mar 20;367(6484):1362–6. 19. Wilens TE. Effects of Methylphenidate on the Catecholaminergic System in Attention- Deficit/Hyperactivity Disorder. Journal of Clinical Psychopharmacology. 2008 Jun;28(3):S46. 20. Moyer JT, Wolf JA, Finkel LH. Effects of Dopaminergic Modulation on the Integrative Properties of the Ventral Striatal Medium Spiny Neuron. Journal of Neurophysiology. 2007 Dec;98(6):3731–48. 21. Carter AG, Soler-Llavina GJ, Sabatini BL. Timing and location of synaptic inputs determinim modes of subthreshold integration in striatal medium spiny neurons. J Neurosci. 2007 Aug 15;27(33):8967–77. 22. Choi EY, Ding SL, Haber SN. Combinatorial Inputs to the Ventral Striatum from the Temporal Cortex, Frontal Cortex, and Amygdala: Implications for Segmenting the Striatum eNeuro. 2017;4(6):ENEURO.0392-17.2017. 23. Korponay C, Choi EY, Haber SN. Corticostriatal Projections of Macaque Area 44. Cereb Cortex Commun. 2020 Nov 5;1(1):tgaa079. 24. Korponay C, Stein EA, Ross TJ. Misconfigured striatal connectivity profiles in smokers. Neuropsychopharmacol. 2022 Nov;47(12):2081–9. 	484 485 486 487	16.	Kodama T, Kojima T, Honda Y, Hosokawa T, Tsutsui K ichiro, Watanabe M. Oral Administration of Methylphenidate (Ritalin) Affects Dopamine Release Differentially Between the Prefrontal Cortex and Striatum: A Microdialysis Study in the Monkey. J Neurosci. 2017 Mar 1;37(9):2387–94.
 18. Westbrook A, van den Bosch R, Määttä JI, Hofmans L, Papadopetraki D, Cools R, et al. Dopamine promotes cognitive effort by biasing the benefits versus costs of cognitive work. Science. 2020 Mar 20;367(6484):1362–6. 19. Wilens TE. Effects of Methylphenidate on the Catecholaminergic System in Attention- Deficit/Hyperactivity Disorder. Journal of Clinical Psychopharmacology. 2008 Jun;28(3):S46. 20. Moyer JT, Wolf JA, Finkel LH. Effects of Dopaminergic Modulation on the Integrative Properties of the Ventral Striatal Medium Spiny Neuron. Journal of Neurophysiology. 2007 Dec;98(6):3731–48. 21. Carter AG, Soler-Llavina GJ, Sabatini BL. Timing and location of synaptic inputs determin- modes of subthreshold integration in striatal medium spiny neurons. J Neurosci. 2007 Aug 15;27(33):8967–77. 22. Choi EY, Ding SL, Haber SN. Combinatorial Inputs to the Ventral Striatum from the Temporal Cortex, Frontal Cortex, and Amygdala: Implications for Segmenting the Striatum eNeuro. 2017;4(6):ENEURO.0392-17.2017. 23. Korponay C, Choi EY, Haber SN. Corticostriatal Projections of Macaque Area 44. Cereb Cortex Commun. 2020 Nov 5;1(1):tgaa079. 24. Korponay C, Stein EA, Ross TJ. Misconfigured striatal connectivity profiles in smokers. Neuropsychopharmacol. 2022 Nov;47(12):2081–9. 	488 489 490	17.	van den Bosch R, Lambregts B, Määttä J, Hofmans L, Papadopetraki D, Westbrook A, et al. Striatal dopamine dissociates methylphenidate effects on value-based versus surprise-based reversal learning. Nat Commun. 2022 Aug 24;13:4962.
 Wilens TE. Effects of Methylphenidate on the Catecholaminergic System in Attention- Deficit/Hyperactivity Disorder. Journal of Clinical Psychopharmacology. 2008 Jun;28(3):S46. Moyer JT, Wolf JA, Finkel LH. Effects of Dopaminergic Modulation on the Integrative Properties of the Ventral Striatal Medium Spiny Neuron. Journal of Neurophysiology. 2007 Dec;98(6):3731–48. Carter AG, Soler-Llavina GJ, Sabatini BL. Timing and location of synaptic inputs determin- modes of subthreshold integration in striatal medium spiny neurons. J Neurosci. 2007 Aug 15;27(33):8967–77. Choi EY, Ding SL, Haber SN. Combinatorial Inputs to the Ventral Striatum from the Temporal Cortex, Frontal Cortex, and Amygdala: Implications for Segmenting the Striatum eNeuro. 2017;4(6):ENEURO.0392-17.2017. Korponay C, Choi EY, Haber SN. Corticostriatal Projections of Macaque Area 44. Cereb Cortex Commun. 2020 Nov 5;1(1):tgaa079. Korponay C, Stein EA, Ross TJ. Misconfigured striatal connectivity profiles in smokers. Neuropsychopharmacol. 2022 Nov;47(12):2081–9. 	491 492 493	18.	Westbrook A, van den Bosch R, Määttä JI, Hofmans L, Papadopetraki D, Cools R, et al. Dopamine promotes cognitive effort by biasing the benefits versus costs of cognitive work. Science. 2020 Mar 20;367(6484):1362–6.
 20. Moyer JT, Wolf JA, Finkel LH. Effects of Dopaminergic Modulation on the Integrative Properties of the Ventral Striatal Medium Spiny Neuron. Journal of Neurophysiology. 2007 Dec;98(6):3731–48. 21. Carter AG, Soler-Llavina GJ, Sabatini BL. Timing and location of synaptic inputs determine modes of subthreshold integration in striatal medium spiny neurons. J Neurosci. 2007 Aug 15;27(33):8967–77. 22. Choi EY, Ding SL, Haber SN. Combinatorial Inputs to the Ventral Striatum from the Temporal Cortex, Frontal Cortex, and Amygdala: Implications for Segmenting the Striatum eNeuro. 2017;4(6):ENEURO.0392-17.2017. 23. Korponay C, Choi EY, Haber SN. Corticostriatal Projections of Macaque Area 44. Cereb Cortex Commun. 2020 Nov 5;1(1):tgaa079. 24. Korponay C, Stein EA, Ross TJ. Misconfigured striatal connectivity profiles in smokers. Neuropsychopharmacol. 2022 Nov;47(12):2081–9. 	494 495 496	19.	Wilens TE. Effects of Methylphenidate on the Catecholaminergic System in Attention- Deficit/Hyperactivity Disorder. Journal of Clinical Psychopharmacology. 2008 Jun;28(3):S46.
 Carter AG, Soler-Llavina GJ, Sabatini BL. Timing and location of synaptic inputs determin modes of subthreshold integration in striatal medium spiny neurons. J Neurosci. 2007 Aug 15;27(33):8967–77. Choi EY, Ding SL, Haber SN. Combinatorial Inputs to the Ventral Striatum from the Temporal Cortex, Frontal Cortex, and Amygdala: Implications for Segmenting the Striatum eNeuro. 2017;4(6):ENEURO.0392-17.2017. Korponay C, Choi EY, Haber SN. Corticostriatal Projections of Macaque Area 44. Cereb Cortex Commun. 2020 Nov 5;1(1):tgaa079. Korponay C, Stein EA, Ross TJ. Misconfigured striatal connectivity profiles in smokers. Neuropsychopharmacol. 2022 Nov;47(12):2081–9. 	497 498 499	20.	Moyer JT, Wolf JA, Finkel LH. Effects of Dopaminergic Modulation on the Integrative Properties of the Ventral Striatal Medium Spiny Neuron. Journal of Neurophysiology. 2007 Dec;98(6):3731–48.
 Choi EY, Ding SL, Haber SN. Combinatorial Inputs to the Ventral Striatum from the Temporal Cortex, Frontal Cortex, and Amygdala: Implications for Segmenting the Striatum eNeuro. 2017;4(6):ENEURO.0392-17.2017. Korponay C, Choi EY, Haber SN. Corticostriatal Projections of Macaque Area 44. Cereb Cortex Commun. 2020 Nov 5;1(1):tgaa079. Korponay C, Stein EA, Ross TJ. Misconfigured striatal connectivity profiles in smokers. Neuropsychopharmacol. 2022 Nov;47(12):2081–9. 	500 501 502	21.	Carter AG, Soler-Llavina GJ, Sabatini BL. Timing and location of synaptic inputs determine modes of subthreshold integration in striatal medium spiny neurons. J Neurosci. 2007 Aug 15;27(33):8967–77.
 Sof 23. Korponay C, Choi EY, Haber SN. Corticostriatal Projections of Macaque Area 44. Cereb Cortex Commun. 2020 Nov 5;1(1):tgaa079. 24. Korponay C, Stein EA, Ross TJ. Misconfigured striatal connectivity profiles in smokers. Neuropsychopharmacol. 2022 Nov;47(12):2081–9. 	503 504 505	22.	Choi EY, Ding SL, Haber SN. Combinatorial Inputs to the Ventral Striatum from the Temporal Cortex, Frontal Cortex, and Amygdala: Implications for Segmenting the Striatum. eNeuro. 2017;4(6):ENEURO.0392-17.2017.
 Korponay C, Stein EA, Ross TJ. Misconfigured striatal connectivity profiles in smokers. Neuropsychopharmacol. 2022 Nov;47(12):2081–9. 	506 507	23.	Korponay C, Choi EY, Haber SN. Corticostriatal Projections of Macaque Area 44. Cereb Cortex Commun. 2020 Nov 5;1(1):tgaa079.
	508 509	24.	Korponay C, Stein EA, Ross TJ. Misconfigured striatal connectivity profiles in smokers. Neuropsychopharmacol. 2022 Nov;47(12):2081–9.

510 511 512	25.	Salimi-Khorshidi G, Douaud G, Beckmann CF, Glasser MF, Griffanti L, Smith SM. Automatic Denoising of Functional MRI Data: Combining Independent Component Analysis and Hierarchical Fusion of Classifiers. NeuroImage. 2014 Apr 4;90:449.
513 514 515	26.	Griffanti L, Salimi-Khorshidi G, Beckmann CF, Auerbach EJ, Douaud G, Sexton CE, et al. ICA-based artefact and accelerated fMRI acquisition for improved Resting State Network imaging. NeuroImage. 2014 Jul 7;95:232.
516 517	27.	Essen DCV, Smith SM, Barch DM, Behrens TEJ, Yacoub E, Ugurbil K, et al. The WU-Minn Human Connectome Project: An Overview. NeuroImage. 2013 Oct 10;80:62.
518 519	28.	Choi EY, Yeo BTT, Buckner RL. The organization of the human striatum estimated by intrinsic functional connectivity. J Neurophysiol. 2012 Oct 15;108(8):2242–63.
520 521 522	29.	Yeo BTT, Krienen FM, Sepulcre J, Sabuncu MR, Lashkari D, Hollinshead M, et al. The organization of the human cerebral cortex estimated by intrinsic functional connectivity. Journal of Neurophysiology. 2011 Sep;106(3):1125.
523 524 525	30.	Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain. NeuroImage. 2002 Jan;15(1):273–89.
526 527	31.	Weber S, Aleman A, Hugdahl K. Involvement of the default mode network under varying levels of cognitive effort. Sci Rep. 2022 Apr 15;12(1):6303.
528 529 530	32.	Hampson M, Driesen N, Roth JK, Gore JC, Constable RT. Functional connectivity between task-positive and task-negative brain areas and its relation to working memory performance. Magnetic Resonance Imaging. 2010 Oct 1;28(8):1051–7.
531 532 533	33.	Sala-Llonch R, Peña-Gómez C, Arenaza-Urquijo EM, Vidal-Piñeiro D, Bargalló N, Junqué C, et al. Brain connectivity during resting state and subsequent working memory task predicts behavioural performance. Cortex. 2012 Oct 1;48(9):1187–96.
534 535 536	34.	Sripada CS, Kessler D, Welsh R, Angstadt M, Liberzon I, Phan KL, et al. Distributed effects of methylphenidate on the network structure of the resting brain: A connectomic pattern classification analysis. NeuroImage. 2013 Nov 1;81:213–21.
537 538 539	35.	Querne L, Fall S, Le Moing AG, Bourel-Ponchel E, Delignières A, Simonnot A, et al. Effects of Methylphenidate on Default-Mode Network/Task-Positive Network Synchronization in Children With ADHD. J Atten Disord. 2017 Dec 1;21(14):1208–20.
540 541	36.	Diedenhofen B, Musch J. cocor: A Comprehensive Solution for the Statistical Comparison of Correlations. PLOS ONE. 2015 Apr 2;10(4):e0121945.
542 543 544	37.	Spreng RN, Stevens WD, Chamberlain JP, Gilmore AW, Schacter DL. Default network activity, coupled with the frontoparietal control network, supports goal-directed cognition. Neuroimage. 2010 Oct 15;53(1):303–17.

545 546	 Andrews-Hanna JR, Reidler JS, Sepulcre J, Poulin R, Buckner RL. Functional-Anatomic Fractionation of the Brain's Default Network. Neuron. 2010 Feb 25;65(4):550–62.
547 548	 Buckner RL, Andrews-Hanna JR, Schacter DL. The Brain's Default Network. Annals of the New York Academy of Sciences. 2008;1124(1):1–38.
549 550 551	40. Turnbull A, Wang HT, Murphy C, Ho NSP, Wang X, Sormaz M, et al. Left dorsolateral prefrontal cortex supports context-dependent prioritisation of off-task thought. Nat Commun. 2019 Aug 23;10:3816.
552 553 554	41. Newman SD, Carpenter PA, Varma S, Just MA. Frontal and parietal participation in problem solving in the Tower of London: fMRI and computational modeling of planning and high-level perception. Neuropsychologia. 2003 Jan 1;41(12):1668–82.
555 556 557	42. Goozee R, O'Daly O, Handley R, Reis Marques T, Taylor H, McQueen G, et al. Effects of aripiprazole and haloperidol on neural activation during a simple motor task in healthy individuals: A functional MRI study. Hum Brain Mapp. 2016 Dec 23;38(4):1833–45.
558 559 560	43. Volkow ND, Fowler JS, Wang GJ, Telang F, Logan J, Wong C, et al. Methylphenidate Decreased the Amount of Glucose Needed by the Brain to Perform a Cognitive Task. PLoS One. 2008 Apr 16;3(4):e2017.
561 562 563	 Devaney KJ, Levin EJ, Tripathi V, Higgins JP, Lazar SW, Somers DC. Attention and Default Mode Network Assessments of Meditation Experience during Active Cognition and Rest. Brain Sciences. 2021 May;11(5):566.
564 565 566 567	45. Cattarinussi G, Di Giorgio A, Moretti F, Bondi E, Sambataro F. Dynamic functional connectivity in schizophrenia and bipolar disorder: A review of the evidence and associations with psychopathological features. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2023 Dec 20;127:110827.
568 569	 Friston KJ. Functional and effective connectivity: a review. Brain connectivity [Internet]. 2011 [cited 2024 Jan 30];1(1). Available from: https://pubmed.ncbi.nlm.nih.gov/22432952/
570 571	47. Haber SN. The primate basal ganglia: parallel and integrative networks. Journal of Chemical Neuroanatomy. 2003 Dec 1;26(4):317–30.
572 573 574	48. King N, Floren S, Kharas N, Thomas M, Dafny N. Glutaminergic signaling in the caudate nucleus is required for behavioral sensitization to methylphenidate. Pharmacol Biochem Behav. 2019 Sep;184:172737.
575 576 577 578	49. Crawford CA, McDougall SA, Meier TL, Collins RL, Watson JB. Repeated methylphenidate treatment induces behavioral sensitization and decreases protein kinase A and dopamine-stimulated adenylyl cyclase activity in the dorsal striatum. Psychopharmacology. 1998 Feb 1;136(1):34–43.
579 580	50. Volkow ND, Wang GJ, Newcorn J, Telang F, Solanto MV, Fowler JS, et al. Depressed Dopamine Activity in Caudate and Preliminary Evidence of Limbic Involvement in Adults

27

- With Attention-Deficit/Hyperactivity Disorder. Archives of General Psychiatry. 2007 Aug
 1;64(8):932–40.
- 51. Schulz KP, Bédard ACV, Fan J, Hildebrandt TB, Stein MA, Ivanov I, et al. Striatal
 Activation Predicts Differential Therapeutic Responses to Methylphenidate and
 Atomoxetine. Journal of the American Academy of Child & Adolescent Psychiatry. 2017 Jul
 1;56(7):602-609.e2.
- 52. Broulidakis MJ, Golm D, Cortese S, Fairchild G, Sonuga-Barke E. Default mode network
 connectivity and attention-deficit/hyperactivity disorder in adolescence: Associations with
 delay aversion and temporal discounting, but not mind wandering. International Journal of
 Psychophysiology. 2022 Mar 1;173:38–44.
- 53. Picon FA, Sato JR, Anés M, Vedolin LM, Mazzola AA, Valentini BB, et al.
 Methylphenidate Alters Functional Connectivity of Default Mode Network in Drug-Naive
 Male Adults With ADHD. J Atten Disord. 2020 Feb;24(3):447–55.
- 54. Gordon EM, Laumann TO, Marek S, Newbold DJ, Hampton JM, Seider NA, et al.
 Individualized Functional Subnetworks Connect Human Striatum and Frontal Cortex. Cereb
 Cortex. 2021 Oct 28;32(13):2868–84.
- 55. Volkow ND, Wang GJ, Fowler JS, Logan J, Franceschi D, Maynard L, et al. Relationship
 between blockade of dopamine transporters by oral methylphenidate and the increases in
 extracellular dopamine: Therapeutic implications. Synapse. 2002;43(3):181–7.
- 56. Sayalı C, van den Bosch R, Määttä JI, Hofmans L, Papadopetraki D, Booij J, et al.
 Methylphenidate undermines or enhances divergent creativity depending on baseline
- dopamine synthesis capacity. Neuropsychopharmacol. 2023 Dec;48(13):1849–58.

603

28

605 Tables and Figures

606

607 <u>Table 1.</u> Demographics of Sample

Demographics			
	Healthy Controls (N = 59)		
Age (years)	39.32 (<i>SD</i> = 11.25)		
Sex (male/female)	17/42		
Race (<i>n</i>)			
Black/African American	11		
White/Caucasian	37		
Asian	5		
More Than One Race	6		
Ethnicity (<i>n</i>)			
Hispanic	9		
Non-Hispanic	49		
Unknown or not reported	1		
Education (<i>n</i>)			
Less than High School	2		
High School Complete/GED	8		
Some / Partial Post-High School	22		
College Graduate/Bachelor's			
Degree	18		
Master's Degree	5		
Professional Degree (MD, JD, Ph.D.)	4		

608 Demographic characterization of sample.



610 Figure 1. Catecholaminergic Agents Significantly Alter Large-Scale Brain Network Temporal Dynamics

haloperidol; FI-DMN: fronto-insular default mode network state; FPN: frontoparietal control network state;
 DMN: default mode network state; DAN: dorsal attention network state; SN-1: salience network state 1;

most negative relative activation; +1 is most positive relative activation. MPH: methylphenidate; HAL:

30

- 520 SMO: sensory motor occipital state; SM-DMN: sensory motor default mode network state; SN-2 salience 521 network state 2. *p_{corr}<0.05, **p_{corr}<0.01, ***p_{corr}<0.001
- 622

Figure 2. DMN-DAN Static Anti-Correlation is Tied to DMN and DAN Temporal Function



624

- Figure 2. A. MPH significantly strengthens DMN-DAN anti-correlation. B. The combination of time spent in
- 626 DMN and DAN negatively predicts DMN-DAN correlation values independently of drug. MPH:
- 627 methylphenidate; HAL: haloperidol; DMN: default mode network; DAN: dorsal attention network.
- 628 **p_{corr}<0.01

31

630 Figure 3. Methylphenidate Significantly Heightens the Magnitude of Rank Order Rearrangement in

631 Corticostriatal Connectivity Profile



632

Figure 3. A. Under MPH, there is significantly higher magnitude of ROR – measure of absolute change in

634 relative corticostriatal connectivity - compared to placebo (within-session placebo rearrangement) and

HAL (HAL-PBO rearrangement). B. Heatmap comparing magnitude of ROR at striatal voxels in MPH-

636 PBO condition compared to within-session placebo condition. Across PBO and MPH conditions, relative

637 connectivity strength between multiple cortical regions and the more **red** striatal voxels is more stable. In

- 638 contrast, more yellow striatal voxels exhibiter greater change in relative connectivity strength with cortical 639 regions under MPH compared to PBO. ROR: rank order rearrangement; MPH: methylphenidate; HAL:
- haloperidol; PBO: placebo. ***p_{corr}<0.001

641

32

Figure 4. Change in Network Temporal Dynamics is Related to Modulation of Functional Corticostriatal Circuitry under Methylphenidate



645

Figure 4. Change in network temporal dynamics is associated with altered corticostriatal rank order

647 rearrangement under MPH. Change in network temporal dynamics is operationalized as the sum, for

each state tested, of the absolute value of the difference in total time spent in the state (MPH-PBO).

Three panels vary by y-axis where left panel y = change in time spent in all states, middle panel y =

change in time spent in only FPN, DMN and DAN states, right panel y = change in time spent in all states
 except FPN, DMN, and DAN states. All Y-axis measures were divided by the number of states summed.

652 MPH: methylphenidate, PBO: placebo; DMN: default mode network; DAN: dorsal attention network; FPN:

653 frontoparietal network.

654

33

- Figure 5. Methylphenidate-Induced Changes in the *Relative* Strength of Connectivity Between Cortical
- 657 Regions and the Dorsal Caudate is Associated with More Time Spent in the Default Mode Network under

658 Methylphenidate.



659

660 Figure 5. A and C. ROR at left dorsal caudate (A) and right dorsal caudate (C), depicting absolute change in relative connectivity between multiple cortical regions and the dorsal caudate node under MPH 661 compared to PBO: Green regions are the data-driven striatal nodes of significant MPH-induced ROR 662 663 previously identified by a voxel-wise paired t-test. Cortical regions are color coded to depict how their relative connectivity strength with the specified caudate node, or 'rank of communication', shifts under 664 MPH compared to under PBO. Regions shown shift at least 5 ranks. Color key at bottom indicates 665 magnitude of change in rank where * indicates a mean magnitude of change for that color - this value 666 only varies by ±2 values at maximum. Exact amount of change per significant cortical region is depicted in 667 668 supplementary material figure S3. B and D. Correlations between ROR at left dorsal caudate (B) and at 669 right dorsal caudate (D) and change in time spent (seconds) in the DMN under MPH compared to PBO. 670 MPH: methylphenidate; PBO: placebo; DMN: default mode network; *pcorr<0.05.